First Trust Exchange Traded Fund Nyse Arca Biotechnology Index Fund Newsroom

Mizuho CEO Sees Global Boom in M&A After Trump Takes Office

BNN BloombergDec 24 16:00

SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?

Seeking AlphaDec 23 05:12

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

BenzingaDec 23 03:51

Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs

Seeking AlphaDec 22 23:12

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

BenzingaDec 22 22:51

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

BenzingaDec 20 23:52

Neurocrine Biosciences Analyst Ratings

BenzingaDec 20 23:50 · Ratings

Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership

BenzingaDec 20 05:24

The Analyst Verdict: Incyte In The Eyes Of 15 Experts

BenzingaDec 20 05:01

(GILD) - Analyzing Gilead Sciences's Short Interest

BenzingaDec 20 03:30

Gilead Raises Assembly Bio Stake to ~30%

Seeking AlphaDec 19 23:42

Wells Fargo Maintains Overweight on Argenx, Raises Price Target to $723

BenzingaDec 19 22:56 · Ratings

Argenx Analyst Ratings

BenzingaDec 19 22:54 · Ratings

Peering Into Exelixis's Recent Short Interest

BenzingaDec 19 03:15

$1000 Invested In Argenx 5 Years Ago Would Be Worth This Much Today

BenzingaDec 18 22:15

Incyte Analyst Ratings

BenzingaDec 18 03:40 · Ratings

Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved With BHV-1300, Gains Analyst Approval

BenzingaDec 18 03:23

Gilead Gets FDA Breakthrough Therapy Status for Trodelvy

Seeking AlphaDec 17 23:57

Expert Outlook: Exelixis Through The Eyes Of 19 Analysts

BenzingaDec 17 21:00

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

BenzingaDec 17 21:00